A dry eye is the absence of sufficient, high-quality tears to moisturize and feed the eye. Tears are essential for preserving the condition of the particular cornea plus for maintaining vision clarity.
New York, Oct. 24, 2022 (GLOBE NEWSWIRE) — Reportlinker. com announces the release of the report “Global Dry Eye Syndrome Treatment Market Size, Share & Industry Trends Analysis Report By Type, Simply by Drug, By Dosage, Simply by Distribution Channel, By Sales Channel, By Product, Simply by Regional Outlook and Forecast, 2022 – 2028” – https://www.reportlinker.com/p06352731/?utm_source=GNW
Dry eye is a prevalent and frequently persistent condition, especially in elderly persons. Tears cover the cornea, which is the particular front layer of the eye, with every blink of the particular eyelids. Tears lubricate the eye surface, reduce the particular likelihood of eye infection, wipe away foreign objects from the vision, and maintain a clear, smooth surface. Extra tears through the eyes drain into tiny ducts inside the eyelids’ inner corners and exit out from the particular back of the nose. When tear generation and drainage are out of balance, dry eye can result.
For clear eyesight, the particular tear film is crucial. Three layers comprise the tear film: an oily coating, a watery layer, plus a mucus layer along with each level having a specific function. The exterior of the tear film is the oily layer. It smoothens the tear’s surface and slows down the rate associated with drying. The meibomian glands in the eye produce this coating. The center of the particular tear film is the watery layer. The particular majority of what is perceived as tears is made up associated with them. By removing international objects from the attention, this level cleanses the eye. The lacrimal glands present in eyelids produce this layer.
The innermost layer of the film is called the mucus layer. This aids within distributing the watery coating and keeping the eye’s moisture. Holes would not adhere to the attention without nasal mucus, which is produced by the particular conjunctiva. This is the transparent tissue that lines the interior of the eyelids and the particular surface associated with the eyesight. Normal rip production keeps eyes moist all the time. The eyes produce a lot of tears when they are inflamed or when someone cries.
COVID-19 Impact Evaluation
Due to fewer ophthalmologist appointments, the COVID-19 pandemic had a negative effect on the dry eye syndrome treatment market in the particular initial stages of the pandemic. But as immediately as the eye care businesses started, the market started to recover. Additionally , the prevalence of dry eye complaints has grown throughout the particular pandemic due to increased screen use and sedentary lifestyles. The particular extrapolation from the results associated with these cases makes it evident that COVID-19 has a positive impact on the market.
Market Growth Factors
Development of promising drugs to manage Dry eyes Diseases
In various age categories, the estimated concentration ranges through roughly 5% to over 35%. Dry eye (DE) is usually overlooked despite being very common. Dry Eye is really a significant burden on the particular public healthcare system because of its detrimental effects on patients’ visual function and life quality. Therefore, efforts in order to improve diagnostic procedures plus develop suitable DE treatments are merited. Reproxalap (Alderya Therapeutics), tivanisiran (Sylentis), tanfanercept (HanAll BioPharma), timbetasin (Regenerx), loteprednol etabonate (Kala Pharma), and NOV03 (Bausch + Lomb) are usually few of the medications that were recently investigated in Phase 3 trials for the treatment of dried out eyes. As these development continue to proceed, they aid in the expansion of the dry eyes symptoms treatment marketplace.
Availability of different procedures and medicines to suit the majority
Burning, Itching, irritation, eyes tiredness, plus ocular inflammation are among the prominent symptoms of DED, which can vary from mild in order to serious and can potentially cause impairment to the particular cornea, conjunctiva, and even loss of eyesight. As the result, the treatment must be customized to each patient by focusing on the distinct mechanisms linked to their condition, depending on the various presentations plus pathophysiology. The tailoring in the medical procedure allows patients to think about the pros and cons before going for therapy. This provides satisfaction and additional comfort to individuals which tremendously helps in the particular success associated with treatment. This particular, in turn, will bolster the growth with the dry eye syndrome treatment market.
Marketplace Restraining Factors
Drug approval takes a longer time
Drug approval entails several expensive regulatory approvals and research phases. About four steps of clinical trials are involved in the drug approval process, as well as various stages of screening by regulatory agencies like the FDA. Because medical trial phases need significant investments, the particular costs associated with unsuccessful trials are also large. For instance, a Forbes article estimates that a drug manufacturer spends roughly $350 million on each treatment before it is introduced to the market. This demonstrates significant medication approval costs that are likely to have an impact in the marketplace for dry eye medicines. In addition , long waiting times also add up to lost money for these manufacturers, plus as such hampers the growth on the dry vision syndrome therapy market.
Based on type, the dry eyes syndrome treatment market will be bifurcated in to evaporative dry eye syndrome and aqueous deficient dry eye syndrome. The particular aqueous dry eyes syndrome segment witnessed a significant revenue share in the particular dry eye symptoms treatment market in 2021. The lack of tear production simply by the lacrimal glands leads to aqueous dry eyes syndrome. Aqueous tear shortage and dry eye can be brought on by persistent inflammation, enlarged tear system, and a concentration of tears inside the lacrimal gland.
On the basis of drug, the dry eyes syndrome therapy market is usually divided into Restasis, Xiidra, Cequa, Eysuvis, Tyrvaya, and others. The restasis medication segment dominated the dry out eye syndrome treatment marketplace with the largest revenue share inside 2021. Symptoms of chronic dry eye are treated with it. Allergan markets the medication , which has a very low incidence of side effects and is widely used by the general public. Despite taking between three and six months to begin treating the illness, the particular medication is widely used as a prescribed drug with excellent therapeutic outcomes.
Based upon product, the dry eye symptoms treatment market is categorized into cyclosporine, topical corticosteroids, artificial holes, punctal plugs, oral omega supplements, as well as others. The cyclosporine segment acquired the maximum revenue discuss in the dry eye syndrome treatment market in 2021. This is a result of cyclosporine-based drugs becoming used with regard to a long time. Research has shown its usefulness for dealing with the signs and symptoms of dry eyes illness. Cyclosporine has been reported in order to decrease T-cell proliferation, a good inflammatory response that contributes to disease.
On the basis of dosage, the particular dry attention syndrome treatment market is segmented into gels, eye solutions, capsules & tablets, eyesight drops, plus ointments. The particular gels section acquired the significant income share within the dry eyes syndrome therapy market in 2021. Gel eye drops tend to remain in a persons vision longer than other forms of eye drops because of their thicker consistency. Solution drops are usually frequently utilized overnight to soothe discomfort and restore moisture to the eyes. They might also give them a shot after trying other, unsuccessful dry eye treatments.
Sales Channel Outlook
Dependent on sales channel, the dry eye syndrome treatment companies are fragmented into prescription and OTC. The doctor prescribed segment witnessed a substantial revenue share inside the dry eyes syndrome therapy market in 2021. The rising occurrence of dry eye in the particular general population is blamed for that market’s expansion. Additionally, prescription vision drops could contain medicines that assist manage ongoing vision issues. A pharmaceutical eye drop called Restasis contains cyclosporine, which relieves the inflammation that leads in order to dry eyes.
Distribution Route Outlook
Based on distribution channel, the dry eyes syndrome treatment market is definitely classified directly into hospital pharmacies, retail medical stores, and online pharmacies. The particular online pharmacies segment obtained a promising revenue reveal inside the dry eye symptoms treatment marketplace in 2021. This can be a consequence of an increase within consumers purchasing goods regarding convenience. Furthermore, due to limits on human migration brought on by the pandemic, online pharmacies have become increasingly popular. Also, many internet retailers’ improved pricing options encourage repeat purchasing.
Based on region, the dry attention syndrome therapy marketplace is analyzed across North America, Europe, Asia Pacific, and LAMEA. The North American region acquired the optimum revenue talk about inside dried out eye syndrome treatment market in 2021. The marketplace in this region is anticipated to be driven by the particular presence associated with a large target population, increased access to health care treatments, and a higher incidence of treatment uptake. Additionally , the market’s lucrativeness draws players to this area. For instance, Sun Pharmaceutical Industries Ltd. introduced Cequa in the area in October 2019.
The major strategies followed by the marketplace participants are Partnerships. Based on the Analysis presented in the particular Cardinal matrix; Novartis AG and Johnson & Manley (Johnson & Johnson Services, Inc. ) are the forerunners from the Dried out Eye Symptoms Treatment Market. Companies such as AbbVie, Inc., Bausch + Lomb Corporation, Sun Pharmaceutic Industries Limited. are some of the key innovators in Dry Vision Syndrome Therapy Market.
The market study report covers the analysis of key stake holders of the market. Key companies profiled in the report include Johnson & Manley (Johnson & Johnson Solutions, Inc. ), AbbVie, Incorporation., Bausch + Lomb Company (Bausch Health Companies, Inc. ), Novartis AG, Sun Pharmaceuticals Industries Ltd., AFT Pharmaceuticals, Santen Pharmaceutical Co., Ltd., Oyster Point Pharma, Inc., OASIS Medical, Incorporation., and Otsuka Pharmaceutical Company., Ltd.
Recent Strategies Deployed in Dry Eye Syndrome Treatment Marketplace
Partnerships, Collaborations and Agreements:
Aug-2022: Bausch + Lomb, a subsidiary of Bausch Health Companies, Inc., formed a partnership with Munich Surgical Imaging, a wholly? owned subsidiary of Heidelberg Engineering. Under this partnership, MSI’s visualization and image guidance expertise, with the inclusion of a good integrated high? speed SS? OCT powered by Heidelberg Engineering had been combined with Bausch + Lomb’s surgical prowess within the cataract, refractive, plus vitreoretinal space. The partnership allowed the particular companies to meet the rising demand intended for digital microscopy.
Jul-2022: Bausch + Lomb Corporation, a subsidiary associated with Bausch Wellness Companies, Inc. partnered along with Novaliq, the biopharmaceutical company focusing on first- and best-in-class ocular therapeutics. Through this collaboration, the companies sought approval to get NOV03 (perfluorohexyloctane) and submitted a New Medication Application (NDA) towards the FOOD AND DRUG ADMINISTRATION. NOV03 (perfluorohexyloctane) is an investigational treatment produced with an indication of treating dry eye disease (DED) and the signs or symptoms that are related to Meibomian gland dysfunction (MGD).
Sep-2021: AbbVie partnered with REGENXBIO, a leading clinical-stage biotechnology company. Under this relationship, AbbVie plus REGENXBIO focused on developing and marketing RGX-314 which is certainly a potential one-time gene therapy meant for the therapy of the wet type of age-related macular degeneration (wet AMD), diabetic retinopathy (DR), and certain other persistent retinal disorders and diseases.
Aug-2021: Oyster Point Pharma came straight into an agreement with Ji Xing Pharmaceuticals, a biotechnology organization headquartered inside Shanghai. Below this agreement, Oyster plus Ji Xing aimed at developing and marketing OC-01 (varenicline) and OC-02 (simpinicline) nasal sprays pertaining to patients in Greater China. The nasal sprays are usually developed meant for the treatment of dry eyesight syndrome and its signs.
Jun-2021: Oyster Point Pharma collaborated along with Adaptive Phage Therapeutics, the clinical-stage business. Through this particular collaboration, Oyster aimed at leveraging APT’s PhageBank technology for your innovation of plausible treatments designed for multiple ophthalmic disorders. The particular collaboration gave Oyster Point Pharma particular rights to achieve an exclusive license intended for developing plus marketing APT’s PhageBank technologies.
Jan-2021: AbbVie formed an agreement with EyecareLive, a digital eye care company focused upon making eyes care accessible and affordable. Under this agreement, EyecareLive provided virtual consultation choices to those bearing associated with chronic dry eyes symptoms. The contract facilitated patients’ access to dry eye treatment through an online consultation with an optometrist who would prescribe appropriate treatments and further assist with connecting in order to eye doctors.
Product Launches and Product Expansions:
Apr-2022: Johnson & Johnson Vision introduced the particular next-generation associated with TearScience Activator Clear meant for the treatment of meibomian glandular dysfunction (MGD). This new technology is developed about the heritage of TearScience LipiFlow Thermal Pulsation System, a completely automated MGD treatment.
Feb-2022: AFT Pharmaceuticals launched Ocuzo, a preservative-free treatment just for bacterial eye infections. Ocuzo may serve as an improved choice for the purpose of patients along with pre-existing ocular surface problems and would minimize the risk of irritation caused by preservatives.
Jan-2022: Sun Pharmaceutical unveiled Cequa, a novel treatment for a dry eye disorder, in Canada. The launch of Cequa in Canada gave entry to remedies to approximately six mil Canadians suffering from dry vision disease.
Dec-2021: AbbVie launched VUITY 1. 25%, pilocarpine HCl ophthalmic solution. Vuity is the first eye fall that has been approved by FDA to treat presbyopia. Presbyopia is the condition of age-related blurry near vision that is diagnosed via a basic attention exam simply by an optometrist or ophthalmologist. It will be a progressing and highly common eyesight condition with which 128 million Americans suffer.
Jul-2021: Oasis Medical revealed Oasis Cry PF Plus lubricant eyes drops. The product comes within a 10mL bottle which is multi-use. An innovative valve present on the tip of the bottle releases the single product drop while simultaneously blocking airflow into the bottle.
Jul-2021: Bausch + Lomb, a subsidiary of Bausch Health Businesses, launched Biotrue Hydration Boost Lubricant Attention Drops and Biotrue Micellar Eyelid Cleansing Wipes in the US. The products are developed as preservative-free with unique formulations consisting of naturally inspired ingredients. The products relieve symptoms associated with inflamed dry eye.
Mar-2021: Oasis Medical released MY OASIS, its patented cyber platform. The cyber platform is usually developed for eye care providers to assist inside building their brand like a dry eyes treatment resource. The platform furthermore helps eye care providers with expanding the reach of their own practice plus providing them entry to options that can improve the quality of life for sufferers suffering through dry eye problems.
Acquisitions and Mergers:
Jun-2022: Novartis obtained Kedalion Therapeutics, a clinical-stage, venture-funded ophthalmic drug firm based in Menlo Park, California. Through this particular acquisition, Novartis attained AcuStreaM technology associated with Kedalion Therapeutics. The acquisition aimed to increase Novartis’ ophthalmics portfolio plus progressed its efforts in order to investigate revolutionizing ophthalmic methods that might assist in addressing unmet individual needs in front-of-eye conditions.
Dec-2021: Novartis took over Gyroscope Therapeutics, a good UK-based ocular gene therapy company. From this acquisition, Novartis built raised the placement inside ophthalmology gene therapy and optogenetics by taking hold of Vedere Bio and Arctos Medical, two prominent companies under Gyroscope Therapeutics. The acquisition aimed to complement Novartis’ excelling expertise in retinal illnesses and gene therapy.
Sep-2020: Santen overtook Eyevance, an US-based ophthalmology company. From this acquisition, Santen took a major step inside contributing to the particular requirements associated with patients struggling with vision-related disorders in the US.
Approvals and Trials:
Mar-2022: Johnson & Manley Vision received FDA authorization for ACUVUE Theravision with Ketotifen, that is an etafilcon A drug-eluting contact lens with ketotifen. Each zoom lens of this item contains 19 mcg ketotifen. ACUVUE Theravision with Ketotifen was the first in an entirely revolutionary category of contact lenses that brought a good extraordinary wearing experience with regard to contact lens wearers along with allergic vision itch.
Oct-2021: Oyster Stage Pharma obtained FDA acceptance for TYRVAYA (varenicline solution) Nasal Spray 0. 03 mg created to the therapy of dry eyes disease and its signs plus symptoms. TYRVAYA Nasal Spray is developed to bind the cholinergic receptors to initiate the particular trigeminal parasympathetic pathway which results in progressive production of the basal rip film and thus assists with promoting the particular dry attention syndrome treatment.
Jun-2021: Santen received FOOD AND DRUG ADMINISTRATION approval regarding Verkazia 0. 1%, a cyclosporine ophthalmic emulsion in order to treat vernal keratoconjunctivitis (VKC). Cyclosporine is known to be effective in treating VKC. Verkazia resists activation associated with T-cells plus reduces immune cells and mediators that will lead to severe, persistent, and weakening allergic swelling of this ocular surface.
Scope of the Study
Market Segments covered in the Report:
• Evaporative Dry Eyesight Syndrome
• Aqueous Deficient Dry Eye Symptoms
• Tyrvaya & Others
• Eyes drops
• Capsules & Tablets
• Eye Solutions
By Distribution Channel
• Retail Pharmacy
• Hospital Pharmacy
• Online Pharmacy
By Product sales Channel
Simply by Product
• Topical Corticosteroids
• Artificial Tears
• Punctal Plugs
• Oral Omega Supplements
• Other people
• Northern America
o Rest of North America
u Rest of European countries
• Asia Pacific
um South Korea
o Rest of Asian countries Pacific
o Saudi Arabia
o South Africa
um Rest associated with LAMEA
• Johnson & Johnson (Johnson & Johnson Services, Incorporation. )
• AbbVie, Inc.
• Bausch + Lomb Corporation (Bausch Health Businesses, Inc. )
• Novartis AG
• Sun Pharmaceutical drugs Industries Ltd.
• BACK Pharmaceuticals
• Santen Pharmaceutical Co., Limited.
• Oyster Point Pharma, Inc.
• OASIS Medical, Inc.
• Otsuka Pharmaceutic Co., Ltd.
• Exhaustive coverage
• Highest number of market tables plus figures
• Subscription based model available
• Guaranteed best price
• Assured post product sales research support with 10% customization free
Read the full report: https://www.reportlinker.com/p06352731/?utm_source=GNW
ReportLinker is an award-winning marketplace research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need – instantly, in one place.
CONTACT: Clare: [email protected] possuindo US: (339)-368-6001 Intl: +1 339-368-6001